Company: OFIX
Filing Date: 2025-04-30
Form Type: DEF 14A
Source: 0000950170-25-061062
Chunk: 36

Company: Orthofix Medical Inc.
Filing Date: 2025-04-30
Form: DEF 14A
Chunk 36
---
Maintain robust stock ownership guidelines for our executive officers and directors, which were recently updated in December 2024

Maintain an incentive compensation clawback policy for executive officers

Include “double-trigger” change in control vesting provisions in all equity grants to executive officers; we have no “single-trigger” cash or similar payment rights for executives upon a change in control

Retain an independent compensation consultant

What we don’t do:

XPay dividends or dividend equivalents on unvested stock options, unvested time-based vesting stock awards, or unearned performance-based vesting stock awards

XHave employment agreements with our executive officers (unless required by law)

XPay excise tax gross-ups for change in control payments

XReprice stock options without shareholder approval

XProvide excessive perquisites

XPermit hedging or pledging of our securities by certain employees considered “insiders”, including our executive officers or directors

<div align='center'>29</div>

Named Executive Officers For 2024, our NEOs were the following individuals:

| Executive                                
 Active officers as of December 31, 2024: 
 Massimo Calafiore                        |     | Position                                                                                                                  
 President and Chief Executive Officer (January 2024-present)                                                              |
|:-----------------------------------------|:----|:--------------------------------------------------------------------------------------------------------------------------|
| Julie Andrews                            |     | Chief Financial Officer (January 2024-present)                                                                            |
| J. Andrés Cedrón                         |     | Chief Legal Officer (April 2024-present)                                                                                  |
| Geoffrey C. Gillespie                    |     | Chief Accounting Officer (January 2024-present); and Former Interim Chief Financial Officer (September 2023-January 2024) |
| Max Reinhardt                            |     | President, Global Spine (June 2024-present)                                                                               |
| Lucas Vitale                             |     | Chief People and Business Operations Officer (March 2024-present)                                                         |
| Former officers:                         |     |                                                                                                                           |
| Catherine M. Burzik                      |     | Interim Chief Executive Officer (September 2023-January 2024)                                                             |
| Kimberley A. Elting                      |     | President, Global Orthopedics (April 2022-July 2024); and Interim Chief Legal Officer (November 2023-April 2024)          |

Executive Leadership Transition During the first eight months of 2024, the Board appointed a new